Nutritional interventions such as fasting are currently under evaluation as anti-cancer treatment. In glioma patient cohorts, the feasibility and safety of fasting in addition to antitumor treatment has been shown. However, it is still unclear whether fasting exerts effects on the glioma tumor tissue at all, and whether fasting causes metabolic or immunological changes in the glioma microenvironment that could be exploited therapeutically. This is a report on the metabolic flexibility of tumor cells induced by a fasting cycle of 72 hours prior to biopsy or resection analyzed by MR-Spectroscopy (MRS) as part of the ERGO3-trial.
No takes yet. Share an insight, caveat, or question.
Alçiçek et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: